The stock jumped 12.2 percent on news of the company’s experimental treatment for osteoporosis preventing fractures. Then, in after-market trading, it's risen more than 2 percent on better-than-expected second-quarter earnings. Actually, profit fell 7.6 percent because of restructuring and acquisition charges. Excluding charges, Amgen's profit rose to $1.14 per share (consensus estimate was $1.02). Amgen shares were in the tank last year on negative news concerning its top-selling anemia drugs, Aranesp and Epogen (studies linked them to heart attacks). But what a difference a promising new drug can make. A trial of 7,800 women with osteoporosis found that denosumab strengthened bones and reduced fractures in the spine and hip more than a placebo. Here are stories from AP and Bloomberg.
More by Mark Lacter:American-US Air settlement with DOJ includes small tweak at LAX
Socal housing market going nowhere fast
Amazon keeps pushing for faster L.A. delivery
Another rugged quarter for Tribune Co. papers
How does Stanford compete with the big boys?
Those awful infographics that promise to explain and only distort
Best to low-ball today's employment report
Further fallout from airport shootings
Crazy opening for Twitter*
Should Twitter be valued at $18 billion?
Recent stories:Letter from Down Under: Welcome to the Homogenocene
One last Florida photo
Signs of Saturday: No refund
'I Am Woman,' hear them roar
New at LA Observed
On the Politics Page
Go to Politics
Sign up for daily email from LA Observed